Have any questions? [email protected] +86-21-58998590
Structure search

ABR-238901


CAS No. : 1638200-22-2

1638200-22-2
Price and Availability of CAS No. : 1638200-22-2
Size Price Stock
5mg $380 In-stock
10mg $600 In-stock
25mg $950 In-stock
50mg $1520 In-stock
100mg $2080 In-stock
200 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-141537
M.Wt: 394.63
Formula: C11H9BrClN3O4S
Purity: >98 %
Solubility: DMSO : 33.33 mg/mL (ultrasonic;warming;heat to 60°C);H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)
Introduction of 1638200-22-2 :

ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research[1][2][3]. In Vivo: ABR-238901 (30 mg/kg/day; gavage; for 3 weeks) causes less angiogenesis and less IL6 and IL10 in MDSCs[1].
ABR-238901 (30 mg/kg/day; gavage) in combination with Bortezomib (0.6 mg/kg; sc; 2 times/week) reduces tumor load compared with treatments of either agent alone[1].
ABR-238901 (30 mg/kg; IP for the first 3 d and thereafter continuously p.o.; daily; for 21 days) leads to gradual deterioration of cardiac function and accelerated left ventricular remodeling in C57BL/6NRJ mice with myocardial ischemia induced by permanent coronary artery ligation. Treatment with ABR-238901 during the first 3 days post-myocardial infarction (MI) restricts the inflammatory damage and promotes a reparatory environment[2].

Your information is safe with us.